Elevance Health, Inc.
ELV
$421.49
-2.28%
Elevance Health, Inc. is one of the largest managed care organizations in the United States, providing employer, individual, and government-sponsored health insurance — including Medicaid and Medicare Advantage — to roughly 45 million medical members, alongside a growing healthcare services arm (Carelon) spanning pharmacy benefit management and care delivery. The company's distinctive identity rests on being the largest single licensee of the Blue Cross Blue Shield brand, operating in 14 states, which gives it deep local market density and pricing power that national peers lack, complemented by acquisitions such as Amerigroup and MMM that extended its government-program footprint. The current investor narrative centers on a margin-recovery and cost-control story: after a turbulent 2025 marked by elevated medical utilization and a weak fourth quarter, management has rebuilt a higher 2026 earnings baseline, with commentary highlighting proven cost programs and sustainable long-term growth. Sentiment has also been supported by a larger-than-expected 2027 Medicare Advantage rate increase from CMS, which improved revenue visibility across the managed care sector and helped drive a sharp re-rating in the shares.…
ELV
Elevance Health, Inc.
$421.49
Related headlines
Investment Opinion: Should I buy ELV Today?
Rating: Buy. The core thesis is that Elevance is a undervalued managed care leader with a tangible margin recovery story, supported by a 2027 Medicare Advantage rate tailwind and a consensus analyst rating of 'buy' (mean 1.82) with an average target of $479.62, implying 9.0% upside. The stock's 13.92x trailing PE and 0.39x PS are at the low end of peers, providing a valuation floor, while the 1.97% dividend yield and $6.29 billion FCF offer income and stability.
Supporting evidence: 1) Operating margin recovered from 1.17% in Q4 2025 to 4.09% in Q2 2026, with net income rising from $547 million to $1.46 billion. 2) Revenue growth is modest at 1.4% YoY, but the Carelon services segment ($19.23 billion) provides a faster-growing, higher-margin diversification lever. 3) Free cash flow of $6.29 billion covers the dividend (27% payout ratio) and buybacks. 4) The average analyst target of $479.62 and high target of $523 reflect confidence in the margin story, with no recent downgrades. 5) The 2027 Medicare Advantage rate increase improves revenue visibility.
Risks and conditions: The biggest risks are a reversal in medical cost trends (which could compress margins back toward 1%), continued revenue stagnation, and valuation compression if the stock's momentum fades. This Buy would downgrade to Hold if operating margin falls below 3% for two consecutive quarters or if revenue growth turns negative. It would upgrade to Strong Buy if operating margin exceeds 5% and revenue growth accelerates above 3%. Relative to its own history (PE range 9.15x to 50.12x) and peers, the stock is fairly valued to slightly undervalued, with the market pricing in modest expectations.
Sign up to view all
ELV 12-Month Price Forecast
The forward-looking view is cautiously bullish. Elevance has shown tangible margin recovery, and the 2027 Medicare Advantage rate increase provides a regulatory tailwind that should support earnings growth. However, revenue growth remains anemic at 1.4%, and the stock's 27% rally leaves it extended near its 52-week high, limiting near-term upside. The base case (50% probability) targets $460-$480, aligned with the analyst average, while the bull case (30%) could reach $523 if margins expand further. I would upgrade to high confidence if operating margin exceeds 5% and revenue growth accelerates above 3%; I would downgrade to neutral if medical cost trends reverse and margin falls below 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $482.38 and implied upside of +14.4% versus the current price.
Average Target
$482.38
0 analysts
Implied Upside
+14.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$406 - $523
Analyst target range
Coverage is robust, with 21 analysts and a consensus recommendation of "buy" (mean rating of 1.82 on a 1-to-5 scale where 1 is a strong buy). The average target price of $479.62 implies roughly +9.0% upside from the current $439.95, a moderate but positive signal that the consensus sees additional room after the stock's 27% one-year run. The distribution of recent ratings skews bullish — Outperform at Bernstein, Buy at Guggenheim and TD Cowen, Overweight at Wells Fargo and Barclays — balanced by Market Perform at Leerink, Sector Perform at RBC, and Neutral at Baird, indicating conviction is strong but not unanimous.
The target range of $406 to $523 is wide, spanning about 29% and signaling meaningful uncertainty about the margin trajectory. The high target of $523 implies roughly 19% upside and likely assumes successful execution on cost programs, Carelon growth, and favorable 2027 Medicare Advantage rate dynamics; the low target of $406 implies about -8% downside and prices in margin compression or adverse medical-cost trends. Notably, the low target sits below the current price, meaning even the most bearish analyst sees limited downside, while the recent institutional ratings show no downgrades — a pattern of stable-to-improving sentiment that supports the constructive consensus.
Bulls vs Bears: ELV Investment Factors
The bull case currently has stronger evidence: margin recovery is tangible (operating margin up from 1.17% to 4.09%), the 2027 Medicare Advantage rate increase provides a regulatory tailwind, and the stock trades at a discount to peers with a 9% upside to the average analyst target. However, the bear case is not without merit—revenue growth of just 1.4% and a 2.90% net margin mean the company is highly sensitive to medical cost trends, and the stock's 27% rally leaves it extended near its 52-week high. The single most important tension is whether the margin recovery is sustainable; if operating margins can hold above 4% and expand further, the stock can re-rate toward the analyst high target of $523, but any reversal in medical cost trends could quickly erase the gains, as evidenced by the -26.49% drawdown in the past year.
Bullish
- Medicare Advantage rate tailwind: The larger-than-expected 2027 Medicare Advantage rate increase from CMS improves revenue visibility across managed care and directly benefits Elevance's government-program segment, which includes Medicare Advantage and Medicaid. This regulatory catalyst has already driven a sharp re-rating in the shares and provides a multi-year earnings tailwind.
- Margin recovery from depressed base: Operating margin recovered from 1.17% in Q4 2025 to 4.09% in Q2 2026, and net income rose from $547 million to $1.46 billion over the same period. The cost-control programs management highlighted are showing tangible results, and further normalization toward historical levels could drive significant EPS growth.
- Attractive valuation with upside: At 13.92x trailing earnings and 0.39x sales, ELV trades at the low end of managed care peers despite a 27% one-year rally. The average analyst target of $479.62 implies 9.0% upside, and the high target of $523 implies 19% upside, suggesting the market has not fully priced in the recovery.
- Strong relative momentum: ELV has outperformed SPY by 11.4 percentage points over the past month and 21.2 points over six months, with relative strength positive across all timeframes. The stock is in a clear uptrend, trading at 93.7% of its 52-week range, and a breakout above $450.69 could invite further momentum flows.
Bearish
- Anemic revenue growth: Q2 2026 revenue grew just 1.4% year-over-year to $50.47 billion, continuing a pattern of low-single-digit expansion. With enrollment growth stagnant and government-program mix shifting, top-line growth is unlikely to accelerate, leaving earnings dependent on cost cuts rather than organic expansion.
- Thin margins vulnerable to utilization: Net margin is only 2.90% and operating margin 4.09%, leaving little cushion if medical utilization spikes. The Q4 2025 net margin of 1.10% illustrates how quickly profitability can erode, and the 89.1% gross margin (on a pass-through basis) means medical cost trends are the dominant swing factor.
- Earnings volatility and lumpy cash flow: Quarterly EPS has swung from $1.84 in Q4 2024 to $9.64 in Q1 2025 to $2.47 in Q4 2025, and free cash flow ranged from -$209 million in Q4 2025 to +$4.10 billion in Q1 2026. This unpredictability complicates valuation and raises the risk of earnings misses.
- Stock extended after sharp rally: ELV is up 27.05% over the past year and 24.19% year-to-date, trading just 2.4% below its 52-week high. The -26.49% maximum drawdown within the past year shows how quickly sentiment can reverse, and the current price leaves little margin of safety for new buyers.
ELV Technical Analysis
Elevance is in a sustained, powerful uptrend: the stock is up 27.05% over the trailing year and 24.19% year-to-date, and at $439.95 it trades at roughly 93.7% of its 52-week range of $274.84 to $450.69. That positioning near the top of the range signals strong momentum rather than a value opportunity, though it also means the stock is extended and vulnerable to profit-taking, as evidenced by the -26.49% maximum drawdown recorded over the past year. The trend structure is clearly higher-highs and higher-lows, with the April 2026 low near $356 giving way to successive breakouts above $400 and $420.
Short-term momentum is accelerating and decisively diverging from the broader market: the stock gained 10.38% over the past month versus a -1.02% decline in SPY (relative strength of +11.40), added 16.49% over three months against SPY's +2.85%, and is up 27.61% over six months versus +6.45% for the index. This is not a mean-reversion bounce but a fresh leg higher — the October rally from $381.67 on October 1 to $439.95 on October 23 occurred on rising conviction, with the most recent session's -1.20% pullback from $445.28 representing only a minor pause. The 1-month, 3-month, 6-month, and 1-year relative strength readings (+11.40, +13.64, +21.16, +13.92) are all positive and broadly aligned, confirming durable outperformance rather than a single-quarter anomaly.
Key technical levels are well defined: resistance sits at the 52-week high of $450.69, roughly 2.4% above the current price, and a clean breakout above that level would confirm the uptrend and likely invite momentum-driven flows. Support is anchored at the 52-week low of $274.84, but more relevant near-term support lies in the $400–$410 zone where the stock consolidated in September, and a breakdown below $400 would signal a failed breakout and a potential trend reversal. With a short ratio of 3.9 days-to-cover and a modest average volume of about 1.17 million shares, the float is not heavily contested by shorts, but the stock's high sensitivity to medical-cost headlines means volatility can spike around earnings; position sizing should account for the -26.49% drawdown experienced within the past year despite the positive annual return.
Beta
0.71
0.71x market volatility
Max Drawdown
-26.5%
Largest decline past year
52-Week Range
$275-$451
Price range past year
Annual Return
+23.1%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +6.4% | -0.2% |
| 3m | +12.1% | +5.5% |
| 6m | +12.0% | +7.1% |
| 1y | +23.1% | +12.3% |
| ytd | +19.0% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue growth is steady but modest: second-quarter 2026 revenue of $50.47 billion grew just 1.4% year-over-year against $49.78 billion in Q2 2025, continuing a pattern of low-single-digit expansion (Q1 2026 revenue of $50.18 billion versus $48.89 billion a year earlier, and Q4 2025's $49.75 billion versus $45.44 billion). The segment mix shows Health Benefits contributing $42.72 billion and Carelon Services $19.23 billion, offset by $12.13 billion in eliminations, underscoring that the insurance core still dominates while the services arm provides a faster-growing, higher-margin diversification lever. For an investor, the takeaway is that Elevance is a mature, scale-driven business where growth comes from government-program mix and Carelon expansion rather than organic enrollment acceleration, making execution on costs the primary earnings driver.
Profitability is thin but improving off a depressed base: Q2 2026 net income was $1.46 billion on a 2.90% net margin, with operating income of $2.06 billion (4.09% operating margin) and EBITDA of $2.10 billion (4.17% EBITDA margin). The quarterly progression is encouraging — net income rose from $547 million in Q4 2025 (1.10% margin) to $1.76 billion in Q1 2026 (3.52% margin) to $1.46 billion in Q2 2026 — while gross margin of 25.56% reflects the pass-through economics typical of managed care, where medical costs consume the vast majority of premium revenue. The reported 89.1% gross margin in the Q2 filing is a presentation artifact of cost-of-revenue classification, so the more meaningful signal is the recovery in operating margin from 1.17% in Q4 2025 to above 4%, consistent with the cost-control narrative driving the stock.
Balance-sheet and cash-flow metrics are solid: debt-to-equity stands at 0.757, the current ratio is 1.24, and trailing free cash flow is $6.29 billion, with Q2 2026 alone generating $1.63 billion of FCF on $1.91 billion of operating cash flow after $287 million of capex. ROE of 12.90% and ROA of 3.93% are respectable for a capital-intensive insurer, and the company returned capital via $373 million of dividends and $234 million of buybacks in the quarter while still repaying $415 million of debt. The main caveat is cash-flow lumpiness — Q4 2025 produced negative FCF of -$209 million and Q1 2026 swung to +$4.10 billion — so investors should focus on the trailing $6.29 billion figure, which comfortably covers the 1.97% dividend yield (payout ratio of 27.0%) and internal growth needs.
Quarterly Revenue
$50.5B
2026-06
Revenue YoY Growth
+1.4%
YoY Comparison
Gross Margin
89.1%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Because Elevance is solidly profitable (Q2 2026 net income of $1.46 billion), the PE ratio is the appropriate primary metric. The stock trades at 13.92x trailing earnings but only 14.56x forward earnings — an unusual configuration where the forward multiple is slightly above the trailing one, implying the market is not pricing in meaningful near-term EPS growth on a trailing basis, though the analyst consensus EPS estimate of $46.21 suggests the forward figure is being computed on a different basis than the reported $6.71 quarterly EPS. On a price-to-sales basis of 0.39x and EV/EBITDA of 10.51x, the stock screens as a low-multiple, value-oriented managed care name rather than a growth compounder.
Relative to the healthcare plans industry, Elevance's 13.92x trailing PE and 0.39x PS are at the low end of the managed care peer group, consistent with its mature growth profile and thin 2.84% net margin; the 10.51x EV/EBITDA multiple is moderate for the sector. The discount appears partly justified by the company's low-single-digit revenue growth (1.4% YoY) and margin volatility, but the 1.77x price-to-book and 1.97% dividend yield provide a valuation floor that limits downside. The negative PEG ratio of -5.70 is a mathematical artifact of prior-period earnings declines and should not be read as a valuation signal.
Historically, Elevance's PE has ranged widely — from 9.15x in Q1 2026 to 50.12x in Q4 2024 and 35.48x in Q4 2025 — reflecting earnings troughs rather than multiple expansion. At 13.92x today, the stock sits in the lower-middle portion of its own multi-year band (versus 2.0x+ PS ratios in 2023–2024 and a current PS of 0.39x), suggesting the market is pricing in modest expectations and that further re-rating depends on sustained margin recovery rather than multiple expansion.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~35x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on Elevance's thin margins and dependence on cost control. Net margin is only 2.90% and operating margin 4.09%, meaning a modest increase in medical utilization could significantly compress earnings; Q4 2025's 1.10% net margin is a recent example of how quickly profitability can deteriorate. Revenue growth is anemic at 1.4% year-over-year, so earnings growth must come from cost programs and mix shift rather than top-line expansion. Additionally, cash flow is lumpy—free cash flow swung from -$209 million in Q4 2025 to +$4.10 billion in Q1 2026—which can complicate capital planning and dividend coverage, though the trailing $6.29 billion FCF comfortably covers the 1.97% dividend yield.
Market and competitive risks include valuation compression and sector rotation. ELV trades at 13.92x trailing earnings, which is at the low end of managed care peers, but the stock has rallied 27% in a year and sits just 2.4% below its 52-week high, leaving little room for error. The managed care sector is highly sensitive to medical cost trends and regulatory changes; the recent CMS rate increase is a positive, but future policy shifts could reverse sentiment. Competition from peers like UnitedHealth and Centene, as well as emerging players like Oscar Health (which raised its 2026 outlook), could pressure margins. The stock's beta is not provided, but its -26.49% maximum drawdown in the past year indicates high volatility around earnings and headlines.
Worst-case scenario: a combination of adverse medical cost trends, failure to sustain margin recovery, and a broad market selloff could drive the stock back toward its 52-week low of $274.84, representing a 37.5% decline from the current $439.95. Even the analyst low target of $406 implies an 8% downside. A more realistic bear case might see the stock retest the $356 April 2026 low (a 19% decline) if Q3 earnings disappoint on medical costs. Investors should be prepared for drawdowns of 20-30% given the stock's history and the thin margin buffer.
FAQ
The key risks are: 1) Financial/operational: thin net margin of 2.90% means a spike in medical utilization could significantly compress earnings, as seen in Q4 2025 when net margin fell to 1.10%. 2) Competitive: peers like UnitedHealth and Centene, as well as emerging players like Oscar Health, could pressure pricing and margins. 3) Macro/regulatory: changes to Medicare Advantage rates or healthcare policy could impact revenue; the recent CMS rate increase is positive but future shifts are uncertain. 4) Company-specific: revenue growth is only 1.4% YoY, and the stock is extended after a 27% rally, with a -26.49% max drawdown in the past year indicating high volatility. The most severe risk is a sustained margin reversal, which could drive the stock toward the 52-week low of $274.84.
The 12-month forecast has three scenarios: bull case (30% probability) targets $500-$523, assuming operating margin expands above 5% and revenue growth accelerates; base case (50%) targets $460-$480, assuming steady margin recovery and low-single-digit revenue growth; bear case (20%) targets $406-$420, assuming margin compression or adverse medical cost trends. The base case is most likely, aligned with the analyst average target of $479.62, implying 9% upside. The key assumption is that operating margin holds around 4-4.5% and no major medical cost surprises occur. The wide analyst target range of $406-$523 reflects uncertainty about the margin trajectory.
ELV appears fairly valued to slightly undervalued. Its trailing PE of 13.92x and price-to-sales of 0.39x are at the low end of the managed care peer group, reflecting its mature growth profile and thin net margin of 2.90%. The forward PE of 14.56x is slightly above trailing, suggesting the market is not pricing in significant near-term EPS growth. Relative to its own history, the PE has ranged from 9.15x to 50.12x, and the current level is in the lower-middle portion, indicating modest expectations. The 1.77x price-to-book and 1.97% dividend yield provide a valuation floor. The market appears to be pricing in continued margin recovery but not aggressive growth, leaving room for upside if execution exceeds expectations.
From a risk/reward perspective, ELV is a good buy for value-oriented investors with a medium risk tolerance. The stock trades at 13.92x trailing earnings, below many managed care peers, and offers 9% upside to the average analyst target of $479.62. The margin recovery story is credible, with operating margin improving from 1.17% to 4.09% over two quarters, and the 2027 Medicare Advantage rate increase provides a tailwind. However, the biggest downside risk is a reversal in medical cost trends, which could compress margins and drive the stock toward the analyst low target of $406 (8% downside) or the 52-week low of $274.84 (37% downside). Given the stock's 27% rally and thin margins, it is best suited for investors who can tolerate volatility and have a longer time horizon.
ELV is more suitable for long-term investment (minimum 2-3 years) given its mature growth profile, low revenue growth of 1.4%, and dividend yield of 1.97%. The margin recovery story and 2027 Medicare Advantage rate tailwind are multi-year catalysts, and the stock's volatility (max drawdown -26.49% in the past year) makes short-term trading risky. The beta is not provided, but the stock's high sensitivity to medical cost headlines means earnings-driven swings can be sharp. Long-term investors can benefit from the dividend, buybacks, and potential multiple expansion as margins normalize. Short-term traders might find opportunities around earnings or CMS announcements, but should use tight stop-losses given the potential for rapid drawdowns.